Szachnowicz S, Duarte A F, Nasi A, da Rocha J R M, Seguro F B, Bianchi E T, Tustumi F, de Moura E G H, Sallum R A A, Cecconello I
Digestive Surgery Division, Department of Gastroenterology, Universidade de Sao Paulo, São Paulo, Brazil.
Endoscopy Unit - Digestive Surgery Division, Department of Gastroenterology, Universidade de Sao Paulo, São Paulo, Brazil.
Dis Esophagus. 2022 Nov 15;35(11). doi: 10.1093/dote/doac026.
The present study aims to compare the effectiveness of surgical and medical therapy in reducing the risk of cancer in Barrett's esophagus in a long-term evaluation. A prospective cohort was designed that compared Barrett's esophagus patients submitted to medical treatment with omeprazole or laparoscopic Nissen fundoplication. The groups were compared using propensity score matching paired by Barrett's esophagus length. A total of 398 patients met inclusion criteria. There were 207 patients in the omeprazole group (Group A) and 191 in the total fundoplication group (Group B). After applying the propensity score matching paired by Barrett's esophagus length, the groups were 180 (Group A) and 190 (Group B). Median follow-up was 80 months. Group B was significantly superior for controlling GERD symptoms. Group B was more efficient than Group A in promoting Barrett's esophagus regression or blocking its progression. Group B was more efficient than Group A in preventing the development of dysplasia and cancer. Logistic regression was performed for the outcomes of adenocarcinoma and dysplasia. Age and body mass index were used as covariates in the logistic regression models. Even after regression analysis, Group B was still superior to Group A to prevent esophageal adenocarcinoma or dysplasia transformation (odds ratio [OR]: 0.51; 95% confidence interval [CI]: 0.27-0.97, for adenocarcinoma or any dysplasia; and OR: 0.26; 95% CI: 0.08-0.81, for adenocarcinoma or high-grade dysplasia). Surgical treatment is superior to medical management, allowing for better symptom control, less need for reflux medication use, higher regression rate of the columnar epithelium and intestinal metaplasia, and lower risk for progression to dysplasia and cancer.
本研究旨在通过长期评估,比较手术治疗和药物治疗在降低巴雷特食管癌症风险方面的有效性。设计了一项前瞻性队列研究,比较接受奥美拉唑药物治疗的巴雷特食管患者和接受腹腔镜尼森胃底折叠术的患者。通过倾向评分匹配,根据巴雷特食管长度对两组进行配对比较。共有398例患者符合纳入标准。奥美拉唑组(A组)有207例患者,全胃底折叠术组(B组)有191例患者。应用根据巴雷特食管长度进行的倾向评分匹配后,两组分别为180例(A组)和190例(B组)。中位随访时间为80个月。B组在控制胃食管反流病症状方面明显更优。B组在促进巴雷特食管消退或阻止其进展方面比A组更有效。B组在预防发育异常和癌症发生方面比A组更有效。对腺癌和发育异常的结局进行了逻辑回归分析。年龄和体重指数被用作逻辑回归模型中的协变量。即使经过回归分析,B组在预防食管腺癌或发育异常转变方面仍优于A组(腺癌或任何发育异常的比值比[OR]:0.51;95%置信区间[CI]:0.27 - 0.97;腺癌或高级别发育异常的OR:0.26;95% CI:0.08 - 0.81)。手术治疗优于药物治疗,能更好地控制症状,减少反流药物的使用需求,柱状上皮和肠化生的消退率更高,进展为发育异常和癌症的风险更低。